Author:
Banerjee Rahul,Marsal Jeffrey,Huang Chiung-Yu,Lo Mimi,Kambhampati Swetha,Kennedy Vanessa E.,Arora Shagun,Wolf Jeffrey L.,Martin Thomas G.,Wong Sandy W.,Shah Nina
Subject
Transplantation,Cell Biology,Hematology,Molecular Medicine,Immunology and Allergy
Reference41 articles.
1. Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in patients with relapsed and refractory multiple myeloma: updated results from phase 1 CRB-401 study;Lin;Blood,2020
2. Updated results from the phase I CRB-402 study of anti-BCMA CAR-T cell therapy bb21217 in patients with relapsed and refractory multiple myeloma: correlation of expansion and duration of response with T cell phenotypes;Alsina;Blood,2020
3. CARTITUDE-1: phase 1b/2 study of ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy, in relapsed/refractory multiple myeloma;Madduri;Blood,2020
4. Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011);Mailankody;J Clin Oncol,2020
5. CAR T-cells in multiple myeloma: state of the art and future directions;Rodriguez-Lobato;Front Oncol,2020
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献